Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases
Martin B. Keller
, Madhukar H. Trivedi
, Michael E. Thase
, Richard C. Shelton
, Susan G. Kornstein
, Charles B. Nemeroff
, Edward S. Friedman
, Alan J. Gelenberg
, James H. Kocsis
, David L. Dunner
, Boadie W. Dunlop
, Robert M. Hirschfeld
, Anthony J. Rothschild
, James M. Ferguson
, Alan F. Schatzberg
, John M. Zajecka
, Ron Pedersen
, Bing Yan
, Saeeduddin Ahmed
, Michael Schmidt
Philip T. Ninan
Show 1 others
Show less
Psychiatry and Behavioral Sciences
Research output
:
Contribution to journal
›
Article
›
peer-review
37
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Recurrent Episodes
100%
Fluoxetine
100%
Acute Phase
100%
Venlafaxine
100%
Continuation Phase
100%
Venlafaxine Extended Release
100%
Sustained Remission
37%
Sustained Response
25%
Response Rate
25%
Remission Rate
25%
Acute Treatment Phase
25%
Quality of Life Assessment
12%
Remission
12%
Treatment Phase
12%
Hamilton Depression Rating Scale (HAM-D)
12%
17-item Hamilton Depression Rating Scale
12%
Relapse Rate
12%
Phase Response
12%
Time to Onset
12%
Comparative Efficacy
12%
Unipolar Major Depression
12%
Comparative Safety
12%
Pharmacology, Toxicology and Pharmaceutical Science
Venlafaxine
100%
Fluoxetine
88%
Remission
66%
Recurrence Risk
11%
Major Depression
11%